Recruiting
Phase 1
Phase 2

D5 ¼NS

Sponsor:

Carilion Clinic

Code:

NCT07937410

Conditions

Chronic Subdural Hematoma

Recurrent

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Dextrose solution

Saline

Study Details

Brief summary:

How can investigators improve recurrence rates of chronic subdural hematomas to reduce need for surgical intervention? Study investigators hypothesize that Dextrose 5% in 0.225% Sodium Chloride (D5 ¼NS) will increase the intracellular brain volume and water content post-operatively, reducing the residual subdural space that is created by evacuation of the chronic subdural hematoma (CSDH), and that this, in turn, will reduce the hematoma volume that will then potentially lead to improved functional outcomes, reduced hospitalization time as well as the reduced rate of symptomatic recurrence requiring redo surgery.

Conditions

Chronic Subdural Hematoma

Recurrent

Study ID

NCT07937410

Start date

Jan 31, 2024

Status verified date

Nov, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Written and voluntarily given informed consent
  • If the patient cannot give informed consent, a legally authorized representative may provide it
  • Male or female 18-100
  • Imaging evidence indicative of cSDH
  • The neurosurgical team has determined that the patient requires surgical evacuation of the cSDH

Exclusion Criteria:

  • significant/symptomatic hyperglycemia; specifically diabetic ketoacidosis or fasting blood glucose level >200 mg/dl
  • Patients with significant hyponatremia (Na <130 mEq/L)
  • Patients who are judged by investigators as being ineligible for participation in the study Patients with a history of relevant drug hypersensitivity Patients who receive another investigational drug shortly before acquisition of consent Women who are pregnant or breastfeeding

Study Design

Enrollment

68 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

placebo comparator: normal saline

normal saline

active comparator: saline with dextrose (D5 ¼NS solutions)

saline with dextrose (D5 ¼NS solutions)

Interventions

Dextrose solution

D5 ¼NS solutions

Saline

normal saline

Primary outcome measure

  • Comparative residual CSDH volume (in mm3) measured and calculated using head CT [ Time Frame: 24 hours after surgery ]

Central Contacts and Locations

Central contacts

Locations

Carilion Clinic

Recruiting

Roanoke, Virginia, United States, 24014

Contacts

Principal Investigator:

Eric Marvin, DO

More Information

Sponsor

Carilion Clinic

Last update posted

Nov 16, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Carilion Clinic on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.